Bavarian Nordic A/S (CPH:BAVA) (OTC:BVNRY), a fully integrated biotechnology company, announced on Tuesday the initiation of the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against the rare, but potentially deadly illness, the equine encephalitis virus.
This programme, which is funded by the US Department of Defence (DOD) Joint Project Manager for Chemical, Biological, Radiation, and Nuclear Medical (JPM CBRN Medical) is a multi-year agreement valued up to USD36m and aims to develop a vaccine against three separate strains of the equine encephalitis virus, Eastern (EEEV), Venezuelan (VEEV) and Western (WEEV), for which there are currently no preventative vaccines available.
According to the company, this phase 1 trial will evaluate the safety, tolerability and immunogenicity of MVA-BN WEV in 45 healthy adults in three treatment groups receiving different doses of the vaccine. Topline results from the study are expected to become available in 2020.
A successful phase 1, based on demonstrating a favourable safety and immunogenicity, could lead to follow-on funding, beyond the initial contract award of USD36m, to support further preclinical, clinical development and manufacturing to support licensure in the US.
Bavarian Nordic is focused on the development of innovative therapies against infectious diseases and cancer.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886